Crowded rheumatoid arthritis category gets JAK reality check, while TNF stalwarts continue to dominate: study
The FDA’s black box label slap on JAK rheumatoid arthritis brands last year hit where it hurt – in class reputation and prescriptions. But Pfizer’s Xeljanz, in the center of the safety storm, has been particularly hard hit.
Almost half (49%) of rheumatologists decreased prescriptions of Xeljanz for patients over the past three months while only 10% increased its use, according to Spherix Global Insights’ most recent quarterly study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.